Currently, several clinical trials are assessing the efficacy of selective complement inhibitors in IgA nephropathy, with promising results showing a reduction in proteinuria and inhibition of route-specific complement activation reported for CFB and MASP-2 inhibitors [50, 51]. Here, MASP2 is linked to IgA glomerulonephritis.